View Post

$30 Million Funding Advances Marburg and Sudan Virus Vaccines

In COVID-19, Latest News by Precision Vaccinations

IAVI announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA) funded additional development and testing of single-dose vaccine candidates against the filoviruses Marburg virus (MARV) and Sudan ebolavirus (SUDV).
BARDA's US$30 million award to the nonprofit IAVI on March 2, 2023, expands the agency's existing support of SUDV vaccine candidate (rVSVΔG-SUDV-GP) development.
The new BARDA funding empowers IAVI and partners to advance the rVSVΔG-SUDV-GP development plan to include a Phase I clinical trial in the United States in 2023.